Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with View All
Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
---|---|---|---|---|---|---|---|
Q2 2022 | ANHYDROUS CITRIC ACID | BUCCAL | FILM, SOLUBLE | 3mg | Correction | ||
Q3 2022 | ANHYDROUS CITRIC ACID | BUCCAL | FILM, SOLUBLE | 2mg | Correction | ||
Q2 2022 | BETADEX | TOPICAL | GEL | 20mg | Correction | ||
Q3 2022 | BETADEX | TOPICAL | GEL | 1.00 %w/w | Correction | ||
Q2 2022 | BUTYL ALCOHOL | ORAL | TABLET, EXTENDED RELEASE | 0.02 mg | Correction | ||
Q3 2022 | BUTYL ALCOHOL | ORAL | TABLET, EXTENDED RELEASE | NA | Correction | ||
Q2 2022 | CROSPOVIDONE | ORAL | TABLET, DELAYED RELEASE | 280mg | Correction | ||
Q3 2022 | CROSPOVIDONE | ORAL | TABLET, DELAYED RELEASE | 224mg | Correction | ||
Q2 2022 | DIBUTYL SEBACATE | ORAL | CAPSULE | 20mg | Correction | ||
Q3 2022 | DIBUTYL SEBACATE | ORAL | CAPSULE | 15mg | Correction | ||
Q2 2022 | EDETATE DISODIUM | INTRAVENOUS | LIQUID | 0.05 %w/v | Correction | ||
Q3 2022 | EDETATE DISODIUM | INTRAVENOUS | LIQUID | 0.03 %w/v | Correction | ||
Q2 2022 | FRUCTOSE | ORAL | TABLET | 137.20 mg | Correction | ||
Q3 2022 | FRUCTOSE | ORAL | TABLET | 64.92 mg | Correction | ||
Q2 2022 | GLYCERIN | NASAL | SPRAY, METERED | 13mg | Correction | ||
Q3 2022 | GLYCERIN | NASAL | SPRAY, METERED | 13mg | Correction | ||
Q2 2022 | HYDROXYPROPYL CELLULOSE | ORAL | TABLET, FILM COATED | 30mg | Correction | ||
Q3 2022 | HYDROXYPROPYL CELLULOSE | ORAL | TABLET, FILM COATED | 25mg | Correction | ||
Q2 2022 | METHYLPARABEN | BUCCAL | FILM, SOLUBLE | 3mg | Correction | ||
Q3 2022 | METHYLPARABEN | BUCCAL | FILM, SOLUBLE | 3mg | Correction | ||
Q2 2022 | POLYCARBOPHIL | BUCCAL | FILM | 2mg | Correction | ||
Q3 2022 | POLYCARBOPHIL | BUCCAL | FILM | 2mg | Correction | ||
Q2 2022 | POLYETHYLENE OXIDE 5000000 | ORAL | TABLET, EXTENDED RELEASE | 284mg | Correction | ||
Q3 2022 | POLYETHYLENE OXIDE 5000000 | ORAL | TABLET, EXTENDED RELEASE | 272mg | Correction | ||
Q2 2022 | SACCHARIN SODIUM | ORAL | TABLET | 84mg | Correction | ||
Q3 2022 | SACCHARIN SODIUM | ORAL | TABLET | 43mg | Correction | ||
Q2 2022 | SODIUM BENZOATE | BUCCAL | FILM, SOLUBLE | 3mg | Correction | ||
Q3 2022 | SODIUM BENZOATE | BUCCAL | FILM, SOLUBLE | 3mg | Correction | ||
Q3 2022 | SODIUM N-(CARBONYL-METHOXYPOLYETHYLENE GLYCOL 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE | INTRAVENOUS | INJECTABLE, LIPOSOMAL | 129mg | Correction | ||
Q2 2022 | SODIUM N-(MPEG 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE | INTRAVENOUS | INJECTION | 0.01 %w/v | Correction | ||
Q3 2022 | SODIUM N-(CARBONYL-METHOXYPOLYETHYLENE GLYCOL 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE | INTRAVENOUS | INJECTION | 1mg | Correction | ||
Q2 2022 | SODIUM PHOSPHATE, MONOBASIC | INTRAVENOUS | INJECTION, SOLUTION | 0.35 %w/v | Correction | ||
Q3 2022 | SODIUM PHOSPHATE, MONOBASIC | INTRAVENOUS | INJECTION, SOLUTION | 27mg | Correction | ||
Q2 2022 | SORBITAN MONOOLEATE | TOPICAL | GEL | 1.00 %w/w | Correction | ||
Q3 2022 | SORBITAN MONOOLEATE | TOPICAL | GEL | 6mg | Correction | ||
Q2 2022 | SORBITOL | ORAL | CAPSULE, LIQUID FILLED | 75mg | Correction | ||
Q3 2022 | SORBITOL | ORAL | CAPSULE, LIQUID FILLED | 51mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | BUCCAL | TABLET | 16.60 mg | Correction | ||
Q3 2022 | STARCH, CORN | BUCCAL | TABLET | 9mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | CAPSULE | 5785mg | Correction | ||
Q3 2022 | STARCH, CORN | ORAL | CAPSULE | 5785mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | CAPSULE, COATED, EXTENDED RELEASE | 19mg | Correction | ||
Q3 2022 | STARCH, CORN | ORAL | CAPSULE, COATED, EXTENDED RELEASE | 19mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | CAPSULE, DELAYED RELEASE | 216mg | Correction | ||
Q3 2022 | STARCH, CORN | ORAL | CAPSULE, DELAYED RELEASE | 216mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | CAPSULE, EXTENDED RELEASE | 194mg | Correction | ||
Q3 2022 | STARCH, CORN | ORAL | CAPSULE, EXTENDED RELEASE | 194mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | CONCENTRATE | NA | Correction | ||
Q3 2022 | STARCH, CORN | ORAL | CONCENTRATE | NA | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | DROPS | NA | Correction | ||
Q3 2022 | STARCH, CORN | ORAL | DROPS | NA | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | LIQUID, EXTENDED RELEASE | 113mg | Correction | ||
Q3 2022 | STARCH, CORN | ORAL | LIQUID, EXTENDED RELEASE | 113mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | PASTILLE | NA | Correction | ||
Q3 2022 | STARCH, CORN | ORAL | PASTILLE | NA | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | POWDER, FOR SUSPENSION | 34mg | Correction | ||
Q3 2022 | STARCH, CORN | ORAL | POWDER, FOR SUSPENSION | 34mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | SUSPENSION | 72.50 mg/ 5.00 ml | Correction | ||
Q3 2022 | STARCH, CORN | ORAL | SUSPENSION | 900mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | SUSPENSION/ DROPS | NA | Correction | ||
Q3 2022 | STARCH, CORN | ORAL | SUSPENSION/ DROPS | 90mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | TABLET | 1116mg | Correction | ||
Q3 2022 | STARCH, CORN | ORAL | TABLET | 1116mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | TABLET, CHEWABLE | 180mg | Correction | ||
Q3 2022 | STARCH, CORN | ORAL | TABLET, CHEWABLE | 180mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | TABLET, COATED | 285.00 mg | Correction | ||
Q3 2022 | STARCH, CORN | ORAL | TABLET, COATED | 256mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | TABLET, DELAYED RELEASE | 240mg | Correction | ||
Q3 2022 | STARCH, CORN | ORAL | TABLET, DELAYED RELEASE | 240mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | TABLET, EXTENDED RELEASE | 184mg | Correction | ||
Q3 2022 | STARCH, CORN | ORAL | TABLET, EXTENDED RELEASE | 184mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | TABLET, FILM COATED | 696mg | Correction | ||
Q3 2022 | STARCH, CORN | ORAL | TABLET, FILM COATED | 696mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 74.30 mg | Correction | ||
Q3 2022 | STARCH, CORN | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 149mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | TABLET, ORALLY DISINTEGRATING | 100mg | Correction | ||
Q3 2022 | STARCH, CORN | ORAL | TABLET, ORALLY DISINTEGRATING | 100mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | 10mg | Correction | ||
Q3 2022 | STARCH, CORN | ORAL | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | 10mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | SUBLINGUAL | TABLET | 409mg | Correction | ||
Q3 2022 | STARCH, CORN | SUBLINGUAL | TABLET | 409mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | VAGINAL | INSERT | 210.00 mg | Correction | ||
Q3 2022 | STARCH, CORN | VAGINAL | INSERT | 4mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | VAGINAL | TABLET | 210.00 mg | Correction | ||
Q3 2022 | STARCH, CORN | VAGINAL | TABLET | 300mg | Correction | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | VAGINAL | TABLET, FILM COATED | 8.00 mg | Correction | ||
Q3 2022 | STARCH, CORN | VAGINAL | TABLET, FILM COATED | 8mg | Correction | ||
Q3 2022 | ACETYLTRIBUTYL CITRATE | ORAL | TABLET, COATED PARTICLES | 18.70 mg | 150mg | Deletion | |
Q3 2022 | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ORAL | CAPSULE, DELAYED RELEASE | 381.00 mg | 381mg | Deletion | |
Q3 2022 | BETADEX SULFOBUTYL ETHER SODIUM | SUBCUTANEOUS | INJECTION, SOLUTION | 40.00 %w/v | Deletion | ||
Q3 2022 | CARBOMER HOMOPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED) | ORAL | TABLET, EXTENDED RELEASE | 175.00 mg | 525mg | Deletion | |
Q3 2022 | FLAVOR CHERRY FT-9496 | ORAL | SOLUTION | 10.00 mg/ 5.00 ml | 233mg | Deletion | |
Q3 2022 | CITRIC ACID MONOHYDRATE | NASAL | AEROSOL, SPRAY | 3.50 mg | Deletion | ||
Q3 2022 | COTTONSEED OIL | NASAL | AEROSOL, SPRAY | 50.50 mg | Deletion | ||
Q3 2022 | CROSPOVIDONE | ORAL | TABLET, MULTILAYER, EXTENDED RELEASE | 5.00 mg | Deletion | ||
Q3 2022 | D&C RED NO. 30 ALUMINUM LAKE | ORAL | TABLET, COATED PARTICLES | 0.80 mg | Deletion | ||
Q3 2022 | D&C RED NO. 33 | ORAL | CAPSULE, DELAYED RELEASE | NA | Deletion | ||
Q3 2022 | DIETHYL PHTHALATE | ORAL | CAPSULE, DELAYED RELEASE PELLETS | 8.89 mg | 9mg | Deletion | |
Q3 2022 | DYE FDC BLUE NO. 40 HT LAKE | ORAL | CAPSULE | 0.16 mg | Deletion | ||
Q3 2022 | DYE FDC BLUE NO. 40 HT LAKE | ORAL | TABLET | 0.23 mg | Deletion | ||
Q3 2022 | EDETATE TRISODIUM | INTRAVENOUS | INJECTION | 0.37 %w/v | Deletion | ||
Q3 2022 | FATTY ACID GLYCERIDES | SUBLINGUAL | SPRAY | 0.96 mg | Deletion | ||
Q3 2022 | FERRIC OXIDE RED | BUCCAL | FILM, SOLUBLE | 0.03 mg | Deletion | ||
Q3 2022 | FERRIC OXIDE RED | ORAL | TABLET, MULTILAYER, EXTENDED RELEASE | 0.11 mg | Deletion | ||
Q3 2022 | FERRIC OXIDE YELLOW | ORAL | TABLET, MULTILAYER, EXTENDED RELEASE | 1.96 mg | Deletion | ||
Q3 2022 | HYPROMELLOSE | ORAL | TABLET, MULTILAYER, EXTENDED RELEASE | 8.40 mg | Deletion | ||
Q3 2022 | HYPROMELLOSE 2906 (4000 MPA.S) | BUCCAL | GUM, CHEWING | 14.00 mg | Deletion | ||
Q3 2022 | HYPROMELLOSE 2910 (15 MPA.S) | ORAL | TABLET, COATED PARTICLES | 42.50 mg | 340mg | Deletion | |
Q3 2022 | HYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MM2/S) | ORAL | TABLET | 19.83 mg | Deletion | ||
Q3 2022 | HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST) | ORAL | TABLET, COATED PARTICLES | 186.9 mg | 1495mg | Deletion | |
Q3 2022 | ICODEXTRIN | ORAL | POWDER, FOR SOLUTION | 12.50 mg/ 5.00 ml | Deletion | ||
Q3 2022 | DEXTRIN | ORAL | SOLUTION | 20.00 mg/ 5.00 ml | 480mg | Deletion | |
Q3 2022 | INK BLACK SW-9009 | ORAL | CAPSULE, EXTENDED RELEASE | NA | Deletion | ||
Q3 2022 | LACTOSE MONOHYDRATE | ORAL | TABLET, COATED PARTICLES | 150.00 mg | Deletion | ||
Q3 2022 | MANNITOL | INTRAVENOUS | LIQUID | 4.05 %w/v | Deletion | ||
Q3 2022 | MEDIUM-CHAIN TRIGLYCERIDES | SUBLINGUAL | SPRAY | 36.70 mg | Deletion | ||
Q3 2022 | OPADRY 03B82849 YELLOW | ORAL | TABLET | 20.00 mg | 40mg | Deletion | |
Q3 2022 | OPASPRAY K-1-2275 YELLOW | ORAL | TABLET | NA | Deletion | ||
Q3 2022 | OPASPRAY K-1-3197 GREEN | ORAL | TABLET | 1.12 mg | Deletion | ||
Q3 2022 | PEPPERMINT OIL | SUBLINGUAL | SPRAY | 0.34 mg | Deletion | ||
Q3 2022 | POLYETHYLENE GLYCOL 3350 | ORAL | TABLET, ORALLY DISINTEGRATING | 1.01 mg | Deletion | ||
Q3 2022 | POLYETHYLENE GLYCOL 400 | ORAL | TABLET, COATED PARTICLES | 12.50 mg | 100mg | Deletion | |
Q3 2022 | POLYETHYLENE GLYCOL 4000 | ORAL | TABLET, MULTILAYER, EXTENDED RELEASE | 2.80 mg | Deletion | ||
Q3 2022 | POLYETHYLENE OXIDE 200000 | ORAL | TABLET | 173.99 mg | 348mg | Deletion | |
Q3 2022 | POLYSORBATE 20 | NASAL | AEROSOL, SPRAY | 27.00 mg | Deletion | ||
Q3 2022 | POLYSTYRENE SULFONIC ACID | ORAL | TABLET | 43.75 mg | Deletion | ||
Q2 2022 | PONCEAU 3R | ORAL | CAPSULE | NA | Deletion | ||
Q2 2022 | PONCEAU 3R | ORAL | CAPSULE, EXTENDED RELEASE | 0.04 mg | Deletion | ||
Q2 2022 | PONCEAU 3R | ORAL | SYRUP | 0.01 mg/ 1.00 ml | Deletion | ||
Q2 2022 | PONCEAU 3R | ORAL | TABLET | 117.20 mg | Deletion | ||
Q2 2022 | PONCEAU 3R | ORAL | TABLET, COATED | 0.26 mg | Deletion | ||
Q2 2022 | PONCEAU 3R | ORAL | TABLET, EXTENDED RELEASE | 0.30 mg | Deletion | ||
Q2 2022 | PONCEAU 3R | ORAL | WAFER | 0.05 mg | Deletion | ||
Q2 2022 | PONCEAU 3R | TOPICAL | SHAMPOO | 1.70 %w/w | Deletion | ||
Q2 2022 | PONCEAU 4R | ORAL | CAPSULE | 0.01 mg | Deletion | ||
Q2 2022 | PONCEAU 4R | ORAL | TABLET | 0.15 mg | Deletion | ||
Q2 2022 | PONCEAU XYLIDINE | ORAL | CAPSULE | NA | Deletion | ||
Q2 2022 | PONCEAU XYLIDINE | ORAL | CAPSULE, EXTENDED RELEASE | NA | Deletion | ||
Q2 2022 | PONCEAU XYLIDINE | ORAL | SOLUTION | 0.05 mg/ 1.00 ml | Deletion | ||
Q2 2022 | PONCEAU XYLIDINE | ORAL | SYRUP | 0.10 mg/ 1.00 ml | Deletion | ||
Q2 2022 | PONCEAU XYLIDINE | ORAL | TABLET | 0.18 mg | Deletion | ||
Q3 2022 | POVIDONE K25 | ORAL | TABLET, MULTILAYER, EXTENDED RELEASE | 1.8 mg | Deletion | ||
Q3 2022 | POVIDONE K30 | ORAL | TABLET, COATED PARTICLES | 3.70 mg | 30mg | Deletion | |
Q3 2022 | POVIDONE K90 | ORAL | TABLET, COATED PARTICLES | 27.60 mg | 221mg | Deletion | |
Q3 2022 | SESAME OIL | ORAL | TABLET, COATED | NA | Deletion | ||
Q3 2022 | SILICA DIMETHYL SILYLATE | TRANSDERMAL | SYSTEM | 38.59 mg | Deletion | ||
Q3 2022 | SODIUM LAURYL SULFATE | ORAL | TABLET, MULTILAYER, EXTENDED RELEASE | 42.50 mg | 43mg | Deletion | |
Q3 2022 | SODIUM PHOSPHATE, DIBASIC | TOPICAL | SOLUTION | 0.50 %w/v | Deletion | ||
Q3 2022 | SORBITAN MONOLAURATE | NASAL | AEROSOL, SPRAY | 22.90 mg | Deletion | ||
Q3 2022 | STEARIC ACID | ORAL | TABLET, COATED PARTICLES | 5.00 mg | 40mg | Deletion | |
Q3 2022 | TERT-BUTYL ALCOHOL | INTRAVENOUS | INJECTION | 0.03 %w/v | Deletion | ||
Q3 2022 | TERT-BUTYL ALCOHOL | SUBCUTANEOUS | INJECTION | 0.03 %w/v | Deletion | ||
Q3 2022 | TITANIUM DIOXIDE | ORAL | TABLET, COATED PARTICLES | 15.00 mg | 120mg | Deletion | |
Q3 2022 | TRISODIUM CITRATE DIHYDRATE | INTRAVENOUS | LIQUID | 0.36 %w/v | Deletion | ||
Q3 2022 | TRISODIUM CITRATE DIHYDRATE | NASAL | AEROSOL, SPRAY | 17.00 mg | Deletion | ||
Q3 2022 | VANILLIN | ORAL | TABLET, COATED PARTICLES | 1.50 mg | 12mg | Deletion | |
Q2 2022 | .ALPHA.-TOCOPHEROL | ORAL | CAPSULE | 5.00 mg | MDE Replacement | ||
Q3 2022 | .ALPHA.-TOCOPHEROL | ORAL | CAPSULE | 16mg | MDE Replacement | ||
Q2 2022 | .ALPHA.-TOCOPHEROL, DL- | ORAL | TABLET, CHEWABLE | 0.02 mg | MDE Replacement | ||
Q3 2022 | .ALPHA.-TOCOPHEROL, DL- | ORAL | TABLET, CHEWABLE | 30mg | MDE Replacement | ||
Q2 2022 | ACETYLTRIBUTYL CITRATE | ORAL | TABLET | 0.56 mg | MDE Replacement | ||
Q3 2022 | ACETYLTRIBUTYL CITRATE | ORAL | TABLET | 150mg | MDE Replacement | ||
Q2 2022 | ACRYLIC ADHESIVE 788 | TRANSDERMAL | SYSTEM | 44.91 mg | MDE Replacement | ||
Q3 2022 | ACRYLIC ADHESIVE 788 | TRANSDERMAL | SYSTEM | 45mg | MDE Replacement | ||
Q2 2022 | ALCOHOL | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 7960.00 mg | MDE Replacement | ||
Q3 2022 | ALCOHOL | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 31840mg | MDE Replacement | ||
Q2 2022 | ANHYDROUS CITRIC ACID | BUCCAL | FILM | 1.04 mg | MDE Replacement | ||
Q3 2022 | ANHYDROUS CITRIC ACID | BUCCAL | FILM | 9mg | MDE Replacement | ||
Q2 2022 | ANHYDROUS CITRIC ACID | ORAL | PASTE | 0.85 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | ANHYDROUS CITRIC ACID | ORAL | PASTE | 26mg | MDE Replacement | ||
Q2 2022 | ANHYDROUS CITRIC ACID | TOPICAL | CLOTH | 4.20 mg | MDE Replacement | ||
Q3 2022 | ANHYDROUS CITRIC ACID | TOPICAL | CLOTH | 4mg | MDE Replacement | ||
Q2 2022 | ANHYDROUS TRISODIUM CITRATE | SUBLINGUAL | FILM | 1.34 mg | MDE Replacement | ||
Q3 2022 | ANHYDROUS TRISODIUM CITRATE | SUBLINGUAL | FILM | 4mg | MDE Replacement | ||
Q2 2022 | ANISE | ORAL | SOLUTION | 5.00 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | ANISE | ORAL | SOLUTION | 72mg | MDE Replacement | ||
Q2 2022 | BENZYL ALCOHOL | INTRAVENOUS | INJECTION, SOLUTION | 180.00 mg | MDE Replacement | ||
Q3 2022 | BENZYL ALCOHOL | INTRAVENOUS | INJECTION, SOLUTION | 400mg | MDE Replacement | ||
Q2 2022 | BETADEX SULFOBUTYL ETHER SODIUM | INTRAVENOUS | INJECTION, SOLUTION | 40.00 %w/v | MDE Replacement | ||
Q3 2022 | BETADEX SULFOBUTYL ETHER SODIUM | INTRAVENOUS | INJECTION, SOLUTION | 13333mg | MDE Replacement | ||
Q2 2022 | BLACK CURRANT | ORAL | SOLUTION | 35.55 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | BLACK CURRANT | ORAL | SOLUTION | 213mg | MDE Replacement | ||
Q2 2022 | BUTYLATED HYDROXYTOLUENE | TOPICAL | GEL | 0.10 %w/w | MDE Replacement | ||
Q3 2022 | BUTYLATED HYDROXYTOLUENE | TOPICAL | GEL | 8mg | MDE Replacement | ||
Q2 2022 | CALCIUM ACETATE | ORAL | SYRUP | 3.00 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | CALCIUM ACETATE | ORAL | SYRUP | 6mg | MDE Replacement | ||
Q2 2022 | CALCIUM STEARATE | ORAL | POWDER | 30.00 mg | MDE Replacement | ||
Q3 2022 | CALCIUM STEARATE | ORAL | POWDER | 600mg | MDE Replacement | ||
Q2 2022 | CARBOMER HOMOPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED) | ORAL | CAPSULE | 8.00 mg | MDE Replacement | ||
Q3 2022 | CARBOMER HOMOPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED) | ORAL | CAPSULE | 16mg | MDE Replacement | ||
Q2 2022 | CARBOXYMETHYLCELLULOSE CALCIUM | ORAL | TABLET | 125.00 mg | MDE Replacement | ||
Q3 2022 | CARBOXYMETHYLCELLULOSE CALCIUM | ORAL | TABLET | 505mg | MDE Replacement | ||
Q2 2022 | CARBOXYMETHYLCELLULOSE SODIUM | ORAL | PASTE | 5.00 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | CARBOXYMETHYLCELLULOSE SODIUM | ORAL | PASTE | 150mg | MDE Replacement | ||
Q2 2022 | CELLULOSE MICROCRYSTALLINE/CARBOXYMETHYLCELLULOSE SODIUM | ORAL | SUSPENSION | 1975 mg | MDE Replacement | ||
Q3 2022 | CELLULOSE MICROCRYSTALLINE/CARBOXYMETHYLCELLULOSE SODIUM | ORAL | SUSPENSION | 71mg | MDE Replacement | ||
Q2 2022 | CHLOROBUTANOL | NASAL | SOLUTION | 5.25 mg | MDE Replacement | ||
Q3 2022 | CHLOROBUTANOL | NASAL | SOLUTION | 2mg | MDE Replacement | ||
Q2 2022 | CITRIC ACID MONOHYDRATE | NASAL | SPRAY, METERED | 1.70 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | CITRIC ACID MONOHYDRATE | NASAL | SPRAY, METERED | 1mg | MDE Replacement | ||
Q2 2022 | CITRIC ACID MONOHYDRATE | ORAL | POWDER, FOR SOLUTION | 315.00 mg | MDE Replacement | ||
Q3 2022 | CITRIC ACID MONOHYDRATE | ORAL | POWDER, FOR SOLUTION | 315mg | MDE Replacement | ||
Q2 2022 | COMPRESSIBLE SUGAR | ORAL | POWDER, FOR SOLUTION | 1851.94 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | COMPRESSIBLE SUGAR | ORAL | POWDER, FOR SOLUTION | 37039mg | MDE Replacement | ||
Q2 2022 | COTTONSEED OIL | INTRAMUSCULAR | INJECTION | 87.46 %w/v | MDE Replacement | ||
Q3 2022 | COTTONSEED OIL | INTRAMUSCULAR | INJECTION | 1084mg | MDE Replacement | ||
Q2 2022 | CROSCARMELLOSE SODIUM | ORAL | SUSPENSION | 143.50 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | CROSCARMELLOSE SODIUM | ORAL | SUSPENSION | 150mg | MDE Replacement | ||
Q2 2022 | CROSPOVIDONE | ORAL | GRANULE, FOR SOLUTION | 36.30 mg | MDE Replacement | ||
Q3 2022 | CROSPOVIDONE | ORAL | GRANULE, FOR SOLUTION | 18mg | MDE Replacement | ||
Q2 2022 | CROSPOVIDONE | ORAL | GRANULE, FOR SUSPENSION | 23.32 mg | MDE Replacement | ||
Q3 2022 | CROSPOVIDONE | ORAL | GRANULE, FOR SUSPENSION | 47mg | MDE Replacement | ||
Q2 2022 | CYCLOMETHICONE 5 | TOPICAL | CREAM, AUGMENTED | 13.00 %w/w | MDE Replacement | ||
Q3 2022 | CYCLOMETHICONE 5 | TOPICAL | CREAM, AUGMENTED | 260mg | MDE Replacement | ||
Q2 2022 | CYSTEINE HYDROCHLORIDE | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 25.00 mg | MDE Replacement | ||
Q3 2022 | CYSTEINE HYDROCHLORIDE | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 100mg | MDE Replacement | ||
Q2 2022 | CYSTEINE HYDROCHLORIDE | INTRAVENOUS | SOLUTION | 0.03 %w/v | MDE Replacement | ||
Q3 2022 | CYSTEINE HYDROCHLORIDE | INTRAVENOUS | SOLUTION | 100mg | MDE Replacement | ||
Q2 2022 | D&C RED NO. 27 | ORAL | TABLET, DELAYED RELEASE | 0.70 mg | MDE Replacement | ||
Q3 2022 | D&C RED NO. 27 | ORAL | TABLET, DELAYED RELEASE | 1mg | MDE Replacement | ||
Q2 2022 | DEXTROSE MONOHYDRATE | NASAL | SPRAY, METERED | 5.00 mg | MDE Replacement | ||
Q3 2022 | DEXTROSE MONOHYDRATE | NASAL | SPRAY, METERED | 20mg | MDE Replacement | ||
Q2 2022 | DIACETYLATED MONOGLYCERIDES | ORAL | CAPSULE, EXTENDED RELEASE | 2.37 mg | MDE Replacement | ||
Q3 2022 | DIACETYLATED MONOGLYCERIDES | ORAL | CAPSULE, EXTENDED RELEASE | 8mg | MDE Replacement | ||
Q2 2022 | DIBASIC POTASSIUM PHOSPHATE | ORAL | SUSPENSION | 1.00 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | DIBASIC POTASSIUM PHOSPHATE | ORAL | SUSPENSION | 24mg | MDE Replacement | ||
Q2 2022 | DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | ORAL | SUSPENSION | 85.00 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | ORAL | SUSPENSION | 255mg | MDE Replacement | ||
Q2 2022 | DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | ORAL | TABLET, DELAYED RELEASE | 2.16 mg | MDE Replacement | ||
Q3 2022 | DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | ORAL | TABLET, DELAYED RELEASE | 4mg | MDE Replacement | ||
Q2 2022 | DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | TRANSDERMAL | SYSTEM | 18.00 mg | MDE Replacement | ||
Q3 2022 | DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | TRANSDERMAL | SYSTEM | 18mg | MDE Replacement | ||
Q2 2022 | DYE ORANGE PB-2148 | ORAL | TABLET | 0.16 mg | MDE Replacement | ||
Q3 2022 | DYE ORANGE PB-2148 | ORAL | TABLET | 1mg | MDE Replacement | ||
Q2 2022 | EDETATE DISODIUM | TOPICAL | CREAM, AUGMENTED | 0.10 %w/w | MDE Replacement | ||
Q3 2022 | EDETATE DISODIUM | TOPICAL | CREAM, AUGMENTED | 2mg | MDE Replacement | ||
Q2 2022 | ETHYL VANILLIN | ORAL | PASTE | 0.22 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | ETHYL VANILLIN | ORAL | PASTE | 7mg | MDE Replacement | ||
Q2 2022 | ETHYLCELLULOSE AQUEOUS DISPERSION TYPE B | ORAL | GRANULE, FOR SUSPENSION | 10.62 mg | MDE Replacement | ||
Q3 2022 | ETHYLCELLULOSE AQUEOUS DISPERSION TYPE B | ORAL | GRANULE, FOR SUSPENSION | 21mg | MDE Replacement | ||
Q2 2022 | ETHYLPARABEN | ORAL | POWDER, FOR SOLUTION | 0.66 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | ETHYLPARABEN | ORAL | POWDER, FOR SOLUTION | 13mg | MDE Replacement | ||
Q2 2022 | FD&C BLUE NO. 1 | SUBLINGUAL | FILM | NA | MDE Replacement | ||
Q3 2022 | FD&C BLUE NO. 1 | SUBLINGUAL | FILM | 0.07 mg | MDE Replacement | ||
Q2 2022 | FD&C BLUE NO. 2 | ORAL | TABLET, FILM COATED | 0.70 mg | MDE Replacement | ||
Q3 2022 | FD&C BLUE NO. 2 | ORAL | TABLET, FILM COATED | 2mg | MDE Replacement | ||
Q2 2022 | FD&C YELLOW NO. 6 | ORAL | POWDER, FOR SUSPENSION | 1.00 mg | MDE Replacement | ||
Q3 2022 | FD&C YELLOW NO. 6 | ORAL | POWDER, FOR SUSPENSION | 6mg | MDE Replacement | ||
Q2 2022 | FLAVOR BANANA GIVAUDAN 85509 | ORAL | SUSPENSION | 2.50 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | FLAVOR BANANA GIVAUDAN 85509 | ORAL | SUSPENSION | 10mg | MDE Replacement | ||
Q2 2022 | FLAVOR CHERRY 594 S.D. | ORAL | SOLUTION | 2.00 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | FLAVOR CHERRY 594 S.D. | ORAL | SOLUTION | 40mg | MDE Replacement | ||
Q2 2022 | FLAVOR CHERRY 842 | ORAL | SOLUTION | 24.72 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | FLAVOR CHERRY 842 | ORAL | SOLUTION | 356mg | MDE Replacement | ||
Q2 2022 | FLAVOR CHERRY PFC-9768 | ORAL | SUSPENSION | 20.00 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | FLAVOR CHERRY PFC-9768 | ORAL | SUSPENSION | 480mg | MDE Replacement | ||
Q2 2022 | FLAVOR GRAPE 61.13252 | ORAL | SOLUTION | 1.00 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | FLAVOR GRAPE 61.13252 | ORAL | SOLUTION | 20mg | MDE Replacement | ||
Q2 2022 | FLAVOR LEMON GIVAUDAN 74940-74 | ORAL | SUSPENSION | 1.08 mg/ml | MDE Replacement | ||
Q3 2022 | FLAVOR LEMON GIVAUDAN 74940-74 | ORAL | SUSPENSION | 43mg | MDE Replacement | ||
Q2 2022 | FLAVOR PEPPERMINT ART F-10012 | ORAL | SUSPENSION | 0.50 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | FLAVOR PEPPERMINT ART F-10012 | ORAL | SUSPENSION | 12mg | MDE Replacement | ||
Q2 2022 | FLAVOR STRAWBERRY WD FO-1022 | ORAL | SOLUTION | 15.00 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | FLAVOR STRAWBERRY WD FO-1022 | ORAL | SOLUTION | 30mg | MDE Replacement | ||
Q2 2022 | FLAVOR TUTTI FRUTTI PERMASEAL 77919-31 | ORAL | SOLUTION | 0.50 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | FLAVOR TUTTI FRUTTI PERMASEAL 77919-31 | ORAL | SOLUTION | 1mg | MDE Replacement | ||
Q2 2022 | FRUCTOSE | ORAL | POWDER, FOR SUSPENSION | 400.00 mg | MDE Replacement | ||
Q3 2022 | FRUCTOSE | ORAL | POWDER, FOR SUSPENSION | 2400mg | MDE Replacement | ||
Q2 2022 | FUMARIC ACID | ORAL | SUSPENSION | 5.00 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | FUMARIC ACID | ORAL | SUSPENSION | 120mg | MDE Replacement | ||
Q2 2022 | GELATIN | SUBLINGUAL | TABLET, ORALLY DISINTEGRATING | 12.50 mg | MDE Replacement | ||
Q3 2022 | GELATIN | SUBLINGUAL | TABLET, ORALLY DISINTEGRATING | 13mg | MDE Replacement | ||
Q2 2022 | GLYCERIN | ORAL | PASTE | 127.40 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | GLYCERIN | ORAL | PASTE | 3822mg | MDE Replacement | ||
Q2 2022 | GLYCERIN | TOPICAL | CREAM, AUGMENTED | 4.00 %w/w | MDE Replacement | ||
Q3 2022 | GLYCERIN | TOPICAL | CREAM, AUGMENTED | 55mg | MDE Replacement | ||
Q2 2022 | GUAR GUM | ORAL | TABLET, EXTENDED RELEASE | 24.00 mg | MDE Replacement | ||
Q3 2022 | GUAR GUM | ORAL | TABLET, EXTENDED RELEASE | 24mg | MDE Replacement | ||
Q2 2022 | HYDROGENATED STARCH HYDROLYSATE | SUBLINGUAL | FILM | 6.02 mg | MDE Replacement | ||
Q3 2022 | HYDROGENATED STARCH HYDROLYSATE | SUBLINGUAL | FILM | 18mg | MDE Replacement | ||
Q2 2022 | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | BUCCAL | FILM | 43.60 mg | MDE Replacement | ||
Q3 2022 | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | BUCCAL | FILM | 87mg | MDE Replacement | ||
Q2 2022 | HYPROMELLOSE 2910 (15 MPA.S) | VAGINAL | INSERT | 36.76 mg | MDE Replacement | ||
Q3 2022 | HYPROMELLOSE 2910 (15 MPA.S) | VAGINAL | INSERT | 37mg | MDE Replacement | ||
Q2 2022 | HYPROMELLOSE 2910 (4000 MPA.S) | OPHTHALMIC | SOLUTION | 0.5 %w/v | MDE Replacement | ||
Q3 2022 | HYPROMELLOSE 2910 (4000 MPA.S) | OPHTHALMIC | SOLUTION | 2mg | MDE Replacement | ||
Q2 2022 | HYPROMELLOSE 2910 (6 MPA.S) | ORAL | GRANULE | 1.00 mg | MDE Replacement | ||
Q3 2022 | HYPROMELLOSE 2910 (6 MPA.S) | ORAL | GRANULE | 18mg | MDE Replacement | ||
Q2 2022 | HYPROMELLOSE 2910 (6 MPA.S) | ORAL | POWDER, FOR SUSPENSION | 35.00 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | HYPROMELLOSE 2910 (6 MPA.S) | ORAL | POWDER, FOR SUSPENSION | 504mg | MDE Replacement | ||
Q2 2022 | LACTOSE MONOHYDRATE | ORAL | GRANULE, FOR SOLUTION | 1691.80 mg | MDE Replacement | ||
Q3 2022 | LACTOSE MONOHYDRATE | ORAL | GRANULE, FOR SOLUTION | 846mg | MDE Replacement | ||
Q2 2022 | LACTOSE MONOHYDRATE | ORAL | TABLET, FOR SUSPENSION | 543.60 mg | MDE Replacement | ||
Q3 2022 | LACTOSE MONOHYDRATE | ORAL | TABLET, FOR SUSPENSION | 2794mg | MDE Replacement | ||
Q2 2022 | LECITHIN | ORAL | SUSPENSION | 110.00 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | LECITHIN | ORAL | SUSPENSION | 150mg | MDE Replacement | ||
Q2 2022 | LIME OIL, COLD PRESSED | ORAL | LOZENGE | 0.42 mg | MDE Replacement | ||
Q3 2022 | LIME OIL, COLD PRESSED | ORAL | LOZENGE | 10mg | MDE Replacement | ||
Q2 2022 | LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE | ORAL | TABLET, DELAYED RELEASE | 30.99 mg | MDE Replacement | ||
Q3 2022 | LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE | ORAL | TABLET, DELAYED RELEASE | 103mg | MDE Replacement | ||
Q2 2022 | MAGNESIUM OXIDE | ORAL | TABLET, DELAYED RELEASE | 367.86 mg | MDE Replacement | ||
Q3 2022 | MAGNESIUM OXIDE | ORAL | TABLET, DELAYED RELEASE | 368mg | MDE Replacement | ||
Q2 2022 | MAGNESIUM STEARATE | ORAL | GRANULE, FOR SUSPENSION | 7.00 mg | MDE Replacement | ||
Q3 2022 | MAGNESIUM STEARATE | ORAL | GRANULE, FOR SUSPENSION | 14mg | MDE Replacement | ||
Q2 2022 | MALTODEXTRIN | ORAL | PASTE | 35.00 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | MALTODEXTRIN | ORAL | PASTE | 1050mg | MDE Replacement | ||
Q2 2022 | MANNITOL | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | 750 mg | MDE Replacement | ||
Q3 2022 | MANNITOL | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | 794mg | MDE Replacement | ||
Q2 2022 | MANNITOL | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 3850.00 mg | MDE Replacement | ||
Q3 2022 | MANNITOL | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 15400mg | MDE Replacement | ||
Q2 2022 | MANNITOL | INTRAVENOUS | SOLUTION | 4.15 %w/v | MDE Replacement | ||
Q3 2022 | MANNITOL | INTRAVENOUS | SOLUTION | 15400mg | MDE Replacement | ||
Q2 2022 | MANNITOL | ORAL | POWDER | 1100.00 mg | MDE Replacement | ||
Q3 2022 | MANNITOL | ORAL | POWDER | 4663mg | MDE Replacement | ||
Q2 2022 | MANNITOL | SUBCUTANEOUS | INJECTION, POWDER, FOR SOLUTION | 20 mg | MDE Replacement | ||
Q3 2022 | MANNITOL | SUBCUTANEOUS | INJECTION, POWDER, FOR SOLUTION | 23mg | MDE Replacement | ||
Q2 2022 | MANNITOL | SUBLINGUAL | TABLET, ORALLY DISINTEGRATING | 10.25 mg | MDE Replacement | ||
Q3 2022 | MANNITOL | SUBLINGUAL | TABLET, ORALLY DISINTEGRATING | 10mg | MDE Replacement | ||
Q2 2022 | MEDIUM-CHAIN TRIGLYCERIDES | ORAL | CAPSULE, EXTENDED RELEASE | 3.08 mg | MDE Replacement | ||
Q3 2022 | MEDIUM-CHAIN TRIGLYCERIDES | ORAL | CAPSULE, EXTENDED RELEASE | 5mg | MDE Replacement | ||
Q2 2022 | MENTHOL | ORAL | LOZENGE | 0.94 mg | MDE Replacement | ||
Q3 2022 | MENTHOL | ORAL | LOZENGE | 23mg | MDE Replacement | ||
Q2 2022 | MENTHOL | SUBLINGUAL | TABLET | 2.00 mg | MDE Replacement | ||
Q3 2022 | MENTHOL | SUBLINGUAL | TABLET | 2mg | MDE Replacement | ||
Q2 2022 | METHYL GLUCOSE SESQUISTEARATE | TOPICAL | CREAM, AUGMENTED | 3.50 %w/w | MDE Replacement | ||
Q3 2022 | METHYL GLUCOSE SESQUISTEARATE | TOPICAL | CREAM, AUGMENTED | 70mg | MDE Replacement | ||
Q2 2022 | METHYLPARABEN | TOPICAL | CREAM, AUGMENTED | 0.20 %w/w | MDE Replacement | ||
Q3 2022 | METHYLPARABEN | TOPICAL | CREAM, AUGMENTED | 2mg | MDE Replacement | ||
Q2 2022 | METHYLPARABEN SODIUM | ORAL | SOLUTION | 2.60 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | METHYLPARABEN SODIUM | ORAL | SOLUTION | 104mg | MDE Replacement | ||
Q2 2022 | MONO AND DIGLYCERIDE | TOPICAL | CREAM | 15.00 %w/w | MDE Replacement | ||
Q3 2022 | MONO AND DIGLYCERIDE | TOPICAL | CREAM | 300mg | MDE Replacement | ||
Q2 2022 | OPADRY II 85F34610 PINK | ORAL | TABLET | 4.00 mg | MDE Replacement | ||
Q3 2022 | OPADRY II 85F34610 PINK | ORAL | TABLET | 8mg | MDE Replacement | ||
Q2 2022 | OPADRY II 85F48105 | ORAL | TABLET | 1.50 mg | MDE Replacement | ||
Q3 2022 | OPADRY II 85F48105 | ORAL | TABLET | 32mg | MDE Replacement | ||
Q2 2022 | OPADRY II YS-1-19025A CLEAR | ORAL | GRANULE, FOR SUSPENSION | 7.08 mg | MDE Replacement | ||
Q3 2022 | OPADRY II YS-1-19025A CLEAR | ORAL | GRANULE, FOR SUSPENSION | 14mg | MDE Replacement | ||
Q2 2022 | OPADRY OY-7300 WHITE | ORAL | TABLET | 35.00 mg | MDE Replacement | ||
Q3 2022 | OPADRY OY-7300 WHITE | ORAL | TABLET | 95mg | MDE Replacement | ||
Q2 2022 | OPADRY YELLOW | ORAL | TABLET, EXTENDED RELEASE | 13.20 mg | MDE Replacement | ||
Q3 2022 | OPADRY YELLOW | ORAL | TABLET, EXTENDED RELEASE | 47mg | MDE Replacement | ||
Q2 2022 | OPADRY YS-1-14129 PINK | ORAL | CAPSULE, EXTENDED RELEASE | 9.00 mg | MDE Replacement | ||
Q3 2022 | OPADRY YS-1-14129 PINK | ORAL | CAPSULE, EXTENDED RELEASE | 9mg | MDE Replacement | ||
Q2 2022 | OPADRY YS-3-7413 CLEAR | ORAL | TABLET, EXTENDED RELEASE | 4.00 mg | MDE Replacement | ||
Q3 2022 | OPADRY YS-3-7413 CLEAR | ORAL | TABLET, EXTENDED RELEASE | 35mg | MDE Replacement | ||
Q2 2022 | PARAFFIN | ORAL | TABLET, EXTENDED RELEASE | 150.20 mg | MDE Replacement | ||
Q3 2022 | PARAFFIN | ORAL | TABLET, EXTENDED RELEASE | 321mg | MDE Replacement | ||
Q2 2022 | PECTIN | ORAL | CAPSULE, EXTENDED RELEASE | 5.447 mg | MDE Replacement | ||
Q3 2022 | PECTIN | ORAL | CAPSULE, EXTENDED RELEASE | 5mg | MDE Replacement | ||
Q2 2022 | PEG-20 METHYL GLUCOSE SESQUISTEARATE | TOPICAL | CREAM, AUGMENTED | 3.50 %w/w | MDE Replacement | ||
Q3 2022 | PEG-20 METHYL GLUCOSE SESQUISTEARATE | TOPICAL | CREAM, AUGMENTED | 70mg | MDE Replacement | ||
Q2 2022 | PEPPERMINT OIL | BUCCAL | FILM | 0.51 mg | MDE Replacement | ||
Q3 2022 | PEPPERMINT OIL | BUCCAL | FILM | 1mg | MDE Replacement | ||
Q2 2022 | PHENOXYETHANOL | TOPICAL | CREAM, AUGMENTED | 1.00 %w/w | MDE Replacement | ||
Q3 2022 | PHENOXYETHANOL | TOPICAL | CREAM, AUGMENTED | 10mg | MDE Replacement | ||
Q2 2022 | POLOXAMER 124 | TOPICAL | GEL | 0.20 %w/w | MDE Replacement | ||
Q3 2022 | POLOXAMER 124 | TOPICAL | GEL | 6mg | MDE Replacement | ||
Q2 2022 | POLOXAMER 188 | ORAL | POWDER, FOR SOLUTION | 25.00 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | POLOXAMER 188 | ORAL | POWDER, FOR SOLUTION | 500mg | MDE Replacement | ||
Q2 2022 | POLOXAMER 188 | ORAL | TABLET, FILM COATED | 16.20 mg | MDE Replacement | ||
Q3 2022 | POLOXAMER 188 | ORAL | TABLET, FILM COATED | 93mg | MDE Replacement | ||
Q2 2022 | POLOXAMER 407 | ORAL | TABLET | 110.00 mg | MDE Replacement | ||
Q3 2022 | POLOXAMER 407 | ORAL | TABLET | 495mg | MDE Replacement | ||
Q2 2022 | POLYETHYLENE GLYCOL 1450 | ORAL | CAPSULE, EXTENDED RELEASE | 17.00 mg | MDE Replacement | ||
Q3 2022 | POLYETHYLENE GLYCOL 1450 | ORAL | CAPSULE, EXTENDED RELEASE | 91mg | MDE Replacement | ||
Q2 2022 | POLYETHYLENE GLYCOL 1450 | TOPICAL | OINTMENT | 43.00 %w/w | MDE Replacement | ||
Q3 2022 | POLYETHYLENE GLYCOL 1450 | TOPICAL | OINTMENT | 921mg | MDE Replacement | ||
Q2 2022 | POLYETHYLENE GLYCOL 300 | INTRAMUSCULAR | SOLUTION | 56.40 %w/v | MDE Replacement | ||
Q3 2022 | POLYETHYLENE GLYCOL 300 | INTRAMUSCULAR | SOLUTION | 16920mg | MDE Replacement | ||
Q2 2022 | POLYETHYLENE GLYCOL 300 | INTRAVENOUS | SOLUTION | 56.40 %w/v | MDE Replacement | ||
Q3 2022 | POLYETHYLENE GLYCOL 300 | INTRAVENOUS | SOLUTION | 16920mg | MDE Replacement | ||
Q2 2022 | POLYETHYLENE GLYCOL 300 | TOPICAL | OINTMENT | 57.00 %w/w | MDE Replacement | ||
Q3 2022 | POLYETHYLENE GLYCOL 300 | TOPICAL | OINTMENT | 1114mg | MDE Replacement | ||
Q2 2022 | POLYETHYLENE GLYCOL 4000 | ORAL | SOLUTION | 66.67 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | POLYETHYLENE GLYCOL 4000 | ORAL | SOLUTION | 2667mg | MDE Replacement | ||
Q2 2022 | POLYETHYLENE GLYCOL 4000 | ORAL | TABLET, DELAYED RELEASE | 1.00 mg | MDE Replacement | ||
Q3 2022 | POLYETHYLENE GLYCOL 4000 | ORAL | TABLET, DELAYED RELEASE | 2mg | MDE Replacement | ||
Q2 2022 | POLYETHYLENE GLYCOL 4500 | ORAL | CAPSULE, EXTENDED RELEASE | 10.00 mg | MDE Replacement | ||
Q3 2022 | POLYETHYLENE GLYCOL 4500 | ORAL | CAPSULE, EXTENDED RELEASE | 53mg | MDE Replacement | ||
Q2 2022 | POLYISOBUTYLENE (1100000 MW) | TRANSDERMAL | SYSTEM | 22.65 mg | MDE Replacement | ||
Q3 2022 | POLYISOBUTYLENE (1100000 MW) | TRANSDERMAL | SYSTEM | 23mg | MDE Replacement | ||
Q2 2022 | POLYSORBATE 20 | ORAL | SUSPENSION | 5.00 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | POLYSORBATE 20 | ORAL | SUSPENSION | 21mg | MDE Replacement | ||
Q2 2022 | POLYSORBATE 80 | ORAL | PASTE | 0.92 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | POLYSORBATE 80 | ORAL | PASTE | 28mg | MDE Replacement | ||
Q2 2022 | POLYSORBATE 80 | ORAL | TABLET, EXTENDED RELEASE | 8.00 mg | MDE Replacement | ||
Q3 2022 | POLYSORBATE 80 | ORAL | TABLET, EXTENDED RELEASE | 8mg | MDE Replacement | ||
Q2 2022 | POLYSORBATE 80 | RECTAL | SOLUTION | 0.10 %w/v | MDE Replacement | ||
Q3 2022 | POLYSORBATE 80 | RECTAL | SOLUTION | 840mg | MDE Replacement | ||
Q2 2022 | POTASSIUM BICARBONATE | ORAL | POWDER, FOR SOLUTION | 500.00 mg | MDE Replacement | ||
Q3 2022 | POTASSIUM BICARBONATE | ORAL | POWDER, FOR SOLUTION | 1000mg | MDE Replacement | ||
Q2 2022 | POTASSIUM CARBONATE | ORAL | TABLET | 25.00 mg | MDE Replacement | ||
Q3 2022 | POTASSIUM CARBONATE | ORAL | TABLET | 60mg | MDE Replacement | ||
Q2 2022 | POTASSIUM SORBATE | ORAL | PASTE | 1.60 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | POTASSIUM SORBATE | ORAL | PASTE | 48mg | MDE Replacement | ||
Q2 2022 | POTASSIUM SORBATE | ORAL | SUSPENSION | 485 mg | MDE Replacement | ||
Q3 2022 | POTASSIUM SORBATE | ORAL | SUSPENSION | 17ng | MDE Replacement | ||
Q2 2022 | POVIDONE K25 | ORAL | TABLET, FILM COATED | 54.47 mg | MDE Replacement | ||
Q3 2022 | POVIDONE K25 | ORAL | TABLET, FILM COATED | 163mg | MDE Replacement | ||
Q2 2022 | POVIDONE K30 | ORAL | CAPSULE, COATED, EXTENDED RELEASE | 15.2 mg | MDE Replacement | ||
Q3 2022 | POVIDONE K30 | ORAL | CAPSULE, COATED, EXTENDED RELEASE | 15mg | MDE Replacement | ||
Q2 2022 | POWDERED CELLULOSE | ORAL | SUSPENSION | 100.00 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | POWDERED CELLULOSE | ORAL | SUSPENSION | 400mg | MDE Replacement | ||
Q2 2022 | PROPYLPARABEN | TOPICAL | CREAM, AUGMENTED | 0.10 %w/w | MDE Replacement | ||
Q3 2022 | PROPYLPARABEN | TOPICAL | CREAM, AUGMENTED | 2mg | MDE Replacement | ||
Q2 2022 | PROSOLV SMCC HD 90 | ORAL | TABLET, DELAYED RELEASE | 195.37 mg | MDE Replacement | ||
Q3 2022 | PROSOLV SMCC HD 90 | ORAL | TABLET, DELAYED RELEASE | 195mg | MDE Replacement | ||
Q2 2022 | PROSOLV SMCC HD 90 | ORAL | TABLET, FILM COATED | 375.52 mg | MDE Replacement | ||
Q3 2022 | PROSOLV SMCC HD 90 | ORAL | TABLET, FILM COATED | 376mg | MDE Replacement | ||
Q2 2022 | SACCHARIN SODIUM | ORAL | GRANULE, FOR SOLUTION | 5.50 mg | MDE Replacement | ||
Q3 2022 | SACCHARIN SODIUM | ORAL | GRANULE, FOR SOLUTION | 3mg | MDE Replacement | ||
Q2 2022 | SACCHARIN SODIUM | ORAL | PASTE | 0.08 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | SACCHARIN SODIUM | ORAL | PASTE | 3mg | MDE Replacement | ||
Q2 2022 | SCOTCHPAK 1022 | TRANSDERMAL | FILM, EXTENDED RELEASE | 904.92 mg | MDE Replacement | ||
Q3 2022 | SCOTCHPAK 1022 | TRANSDERMAL | FILM, EXTENDED RELEASE | 2335mg | MDE Replacement | ||
Q2 2022 | SILICON DIOXIDE | ORAL | CAPSULE, EXTENDED RELEASE | 106.00 mg | MDE Replacement | ||
Q3 2022 | SILICON DIOXIDE | ORAL | CAPSULE, EXTENDED RELEASE | 168mg | MDE Replacement | ||
Q2 2022 | SILICON DIOXIDE | ORAL | GRANULE, FOR SOLUTION | 1.80 mg | MDE Replacement | ||
Q3 2022 | SILICON DIOXIDE | ORAL | GRANULE, FOR SOLUTION | 3mg | MDE Replacement | ||
Q2 2022 | SILICON DIOXIDE | ORAL | POWDER | 100.00 mg | MDE Replacement | ||
Q3 2022 | SILICON DIOXIDE | ORAL | POWDER | 602mg | MDE Replacement | ||
Q2 2022 | SIMETHICONE | ORAL | POWDER, FOR SOLUTION | 0.40 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | SIMETHICONE | ORAL | POWDER, FOR SOLUTION | 8mg | MDE Replacement | ||
Q2 2022 | SIMETHICONE EMULSION | ORAL | PASTE | 1.80 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | SIMETHICONE EMULSION | ORAL | PASTE | 54mg | MDE Replacement | ||
Q2 2022 | SIMETHICONE EMULSION | ORAL | SOLUTION | 0.08 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | SIMETHICONE EMULSION | ORAL | SOLUTION | 2mg | MDE Replacement | ||
Q2 2022 | SIMETHICONE EMULSION | ORAL | SUSPENSION | 350 mg | MDE Replacement | ||
Q3 2022 | SIMETHICONE EMULSION | ORAL | SUSPENSION | 13mg | MDE Replacement | ||
Q2 2022 | SODIUM BENZOATE | ORAL | PASTE | 0.92 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | SODIUM BENZOATE | ORAL | PASTE | 28mg | MDE Replacement | ||
Q2 2022 | SODIUM BENZOATE | ORAL | POWDER, FOR SOLUTION | 98.00 mg | MDE Replacement | ||
Q3 2022 | SODIUM BENZOATE | ORAL | POWDER, FOR SOLUTION | 98mg | MDE Replacement | ||
Q2 2022 | SODIUM BENZOATE | ORAL | SOLUTION | 330.00 mg | MDE Replacement | ||
Q3 2022 | SODIUM BENZOATE | ORAL | SOLUTION | 660mg | MDE Replacement | ||
Q2 2022 | SODIUM BICARBONATE | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 573.50 mg | MDE Replacement | ||
Q3 2022 | SODIUM BICARBONATE | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 3059mg | MDE Replacement | ||
Q2 2022 | SODIUM BISULFITE | ORAL | SUSPENSION | 2.00 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | SODIUM BISULFITE | ORAL | SUSPENSION | 5mg | MDE Replacement | ||
Q2 2022 | SODIUM CHLORIDE | INTRAVENOUS | SOLUTION | 9.00 mg | MDE Replacement | ||
Q3 2022 | SODIUM CHLORIDE | INTRAVENOUS | SOLUTION | 90mg | MDE Replacement | ||
Q2 2022 | SODIUM CHLORIDE | SUBMUCOSAL | INJECTION | 0.16 %w/v | MDE Replacement | ||
Q3 2022 | SODIUM CHLORIDE | SUBMUCOSAL | INJECTION | 17mg | MDE Replacement | ||
Q2 2022 | SODIUM HYDROXIDE | ORAL | TABLET, FILM COATED | 1.50 mg | MDE Replacement | ||
Q3 2022 | SODIUM HYDROXIDE | ORAL | TABLET, FILM COATED | 8mg | MDE Replacement | ||
Q2 2022 | SODIUM LAURYL SULFATE | ORAL | TABLET, FOR SUSPENSION | 48.00 mg | MDE Replacement | ||
Q3 2022 | SODIUM LAURYL SULFATE | ORAL | TABLET, FOR SUSPENSION | 264mg | MDE Replacement | ||
Q2 2022 | SODIUM METABISULFITE | SUBMUCOSAL | INJECTION | 0.05 %w/v | MDE Replacement | ||
Q3 2022 | SODIUM METABISULFITE | SUBMUCOSAL | INJECTION | 5mg | MDE Replacement | ||
Q2 2022 | SODIUM N-(MPEG 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE | INTRAVENOUS | INJECTABLE, LIPOSOMAL | 0.32 %w/v | MDE Replacement | ||
Q3 2022 | SODIUM N-(CARBONYL-METHOXYPOLYETHYLENE GLYCOL 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE | INTRAVENOUS | INJECTABLE, LIPOSOMAL | 129mg | MDE Replacement | ||
Q2 2022 | SODIUM N-(MPEG 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE | INTRAVENOUS | INJECTION | 0.01 %w/v | MDE Replacement | ||
Q3 2022 | SODIUM N-(CARBONYL-METHOXYPOLYETHYLENE GLYCOL 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE | INTRAVENOUS | INJECTION | 1mg | MDE Replacement | ||
Q2 2022 | SODIUM PHOSPHATE, DIBASIC | INTRAVENOUS | SOLUTION | 0.01 %w/v | MDE Replacement | ||
Q3 2022 | SODIUM PHOSPHATE, DIBASIC | INTRAVENOUS | SOLUTION | 52mg | MDE Replacement | ||
Q2 2022 | SODIUM PHOSPHATE, DIBASIC, DIHYDRATE | INTRAVENOUS | INJECTION | 0.24 %w/v | MDE Replacement | ||
Q3 2022 | SODIUM PHOSPHATE, DIBASIC, DIHYDRATE | INTRAVENOUS | INJECTION | 55mg | MDE Replacement | ||
Q2 2022 | SODIUM PHOSPHATE, DIBASIC, DIHYDRATE | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.04 %w/v | MDE Replacement | ||
Q3 2022 | SODIUM PHOSPHATE, DIBASIC, DIHYDRATE | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 3mg | MDE Replacement | ||
Q2 2022 | SODIUM PHOSPHATE, DIBASIC, DIHYDRATE | NASAL | SPRAY | 3.00 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | SODIUM PHOSPHATE, DIBASIC, DIHYDRATE | NASAL | SPRAY | 12mg | MDE Replacement | ||
Q2 2022 | SODIUM PHOSPHATE, DIBASIC, DIHYDRATE | SUBCUTANEOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.04 %w/v | MDE Replacement | ||
Q3 2022 | SODIUM PHOSPHATE, DIBASIC, DIHYDRATE | SUBCUTANEOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 3mg | MDE Replacement | ||
Q2 2022 | SODIUM PHOSPHATE, DIBASIC, DODECAHYDRATE | NASAL | SPRAY | 6.64 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | SODIUM PHOSPHATE, DIBASIC, DODECAHYDRATE | NASAL | SPRAY | 7mg | MDE Replacement | ||
Q2 2022 | SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE | OPHTHALMIC | SOLUTION/ DROPS | 0.55 %w/v | MDE Replacement | ||
Q3 2022 | SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE | OPHTHALMIC | SOLUTION/ DROPS | 43mg | MDE Replacement | ||
Q2 2022 | SODIUM PHOSPHATE, MONOBASIC | INTRAVENOUS | INJECTION, SOLUTION | 0.35 %w/v | MDE Replacement | ||
Q3 2022 | SODIUM PHOSPHATE, MONOBASIC | INTRAVENOUS | INJECTION, SOLUTION | 27mg | MDE Replacement | ||
Q2 2022 | SODIUM PHOSPHATE, MONOBASIC | ORAL | TABLET | 1.38 mg | MDE Replacement | ||
Q3 2022 | SODIUM PHOSPHATE, MONOBASIC | ORAL | TABLET | 1mg | MDE Replacement | ||
Q2 2022 | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | ORAL | SUSPENSION | 2225 mg | MDE Replacement | ||
Q3 2022 | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | ORAL | SUSPENSION | 80mg | MDE Replacement | ||
Q2 2022 | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SUBCUTANEOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.64 mg | MDE Replacement | ||
Q3 2022 | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | SUBCUTANEOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2mg | MDE Replacement | ||
Q2 2022 | SODIUM STARCH GLYCOLATE TYPE A | ORAL | TABLET, FOR SUSPENSION | 30.00 mg | MDE Replacement | ||
Q3 2022 | SODIUM STARCH GLYCOLATE TYPE A | ORAL | TABLET, FOR SUSPENSION | 165mg | MDE Replacement | ||
Q2 2022 | SODIUM STARCH GLYCOLATE TYPE A | ORAL | TABLET, ORALLY DISINTEGRATING | 71.43 mg | MDE Replacement | ||
Q3 2022 | SODIUM STARCH GLYCOLATE TYPE A | ORAL | TABLET, ORALLY DISINTEGRATING | 29mg | MDE Replacement | ||
Q2 2022 | SODIUM STEARYL FUMARATE | ORAL | CAPSULE | 15.00 mg | MDE Replacement | ||
Q3 2022 | SODIUM STEARYL FUMARATE | ORAL | CAPSULE | 180mg | MDE Replacement | ||
Q2 2022 | SODIUM STEARYL FUMARATE | ORAL | CAPSULE, EXTENDED RELEASE | 7.00 mg | MDE Replacement | ||
Q3 2022 | SODIUM STEARYL FUMARATE | ORAL | CAPSULE, EXTENDED RELEASE | 11mg | MDE Replacement | ||
Q2 2022 | SODIUM STEARYL FUMARATE | ORAL | GRANULE, FOR SOLUTION | 18.20 mg | MDE Replacement | ||
Q2 2022 | SODIUM STEARYL FUMARATE | ORAL | GRANULE, FOR SOLUTION | 18.20 mg | MDE Replacement | ||
Q3 2022 | SODIUM STEARYL FUMARATE | ORAL | GRANULE, FOR SOLUTION | 1mg | MDE Replacement | ||
Q3 2022 | SODIUM STEARYL FUMARATE | ORAL | GRANULE, FOR SOLUTION | 9mg | MDE Replacement | ||
Q2 2022 | SODIUM THIOSULFATE | INTRAVENOUS | INJECTION | 4.00 mg | MDE Replacement | ||
Q3 2022 | SODIUM THIOSULFATE | INTRAVENOUS | INJECTION | 18mg | MDE Replacement | ||
Q2 2022 | SORBITAN MONOOLEATE | TOPICAL | GEL | 1.00 %w/w | MDE Replacement | ||
Q3 2022 | SORBITAN MONOOLEATE | TOPICAL | GEL | 6mg | MDE Replacement | ||
Q2 2022 | SORBITOL | INTRAVENOUS | INJECTION, SOLUTION | 30.00 %w/v | MDE Replacement | ||
Q3 2022 | SORBITOL | INTRAVENOUS | INJECTION, SOLUTION | 3000mg | MDE Replacement | ||
Q2 2022 | SORBITOL | NASAL | SPRAY | 6.17 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | SORBITOL | NASAL | SPRAY | 49mg | MDE Replacement | ||
Q2 2022 | SORBITOL SOLUTION | ORAL | SUSPENSION | 35430 mg | MDE Replacement | ||
Q3 2022 | SORBITOL SOLUTION | ORAL | SUSPENSION | 1275mg | MDE Replacement | ||
Q2 2022 | SQUALANE | TOPICAL | CREAM, AUGMENTED | 6.00 %w/w | MDE Replacement | ||
Q3 2022 | SQUALANE | TOPICAL | CREAM, AUGMENTED | 120mg | MDE Replacement | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | SUSPENSION | 72.50 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | STARCH, CORN | ORAL | SUSPENSION | 900mg | MDE Replacement | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | SUSPENSION/ DROPS | NA | MDE Replacement | ||
Q3 2022 | STARCH, CORN | ORAL | SUSPENSION/ DROPS | 90mg | MDE Replacement | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | TABLET, COATED | 285.00 mg | MDE Replacement | ||
Q3 2022 | STARCH, CORN | ORAL | TABLET, COATED | 256mg | MDE Replacement | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 74.30 mg | MDE Replacement | ||
Q3 2022 | STARCH, CORN | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 149mg | MDE Replacement | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | VAGINAL | TABLET | 210.00 mg | MDE Replacement | ||
Q3 2022 | STARCH, CORN | VAGINAL | TABLET | 300mg | MDE Replacement | ||
Q2 2022 | STARCH 1500, PREGELATINIZED | VAGINAL | TABLET, FILM COATED | 8.00 mg | MDE Replacement | ||
Q3 2022 | STARCH, CORN | VAGINAL | TABLET, FILM COATED | 8mg | MDE Replacement | ||
Q2 2022 | STEARIC ACID | ORAL | CAPSULE, EXTENDED RELEASE | 25.50 mg | MDE Replacement | ||
Q3 2022 | STEARIC ACID | ORAL | CAPSULE, EXTENDED RELEASE | 64mg | MDE Replacement | ||
Q2 2022 | STEAROYL POLYOXYLGLYCERIDES | ORAL | CAPSULE | 480.00 mg | MDE Replacement | ||
Q3 2022 | STEAROYL POLYOXYLGLYCERIDES | ORAL | CAPSULE | 960mg | MDE Replacement | ||
Q2 2022 | STRAWBERRY | ORAL | SUSPENSION | 0.70 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | STRAWBERRY | ORAL | SUSPENSION | 21mg | MDE Replacement | ||
Q2 2022 | SUCRALOSE | NASAL | SPRAY, METERED | 1.50 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | SUCRALOSE | NASAL | SPRAY, METERED | 12mg | MDE Replacement | ||
Q2 2022 | SUCROSE | ORAL | CAPSULE, COATED, EXTENDED RELEASE | 86.01 mg | MDE Replacement | ||
Q3 2022 | SUCROSE | ORAL | CAPSULE, COATED, EXTENDED RELEASE | 86mg | MDE Replacement | ||
Q2 2022 | SUCROSE | SUBCUTANEOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 4.25 %w/v | MDE Replacement | ||
Q3 2022 | SUCROSE | SUBCUTANEOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 308mg | MDE Replacement | ||
Q2 2022 | SUCROSE STEARATE | ORAL | TABLET, EXTENDED RELEASE | 44.56 mg | MDE Replacement | ||
Q3 2022 | SUCROSE STEARATE | ORAL | TABLET, EXTENDED RELEASE | 57mg | MDE Replacement | ||
Q2 2022 | TALC | ORAL | CAPSULE, COATED, EXTENDED RELEASE | 20.35 mg | MDE Replacement | ||
Q3 2022 | TALC | ORAL | CAPSULE, COATED, EXTENDED RELEASE | 20mg | MDE Replacement | ||
Q2 2022 | TITANIUM DIOXIDE | BUCCAL | FILM | 1.66 mg | MDE Replacement | ||
Q3 2022 | TITANIUM DIOXIDE | BUCCAL | FILM | 3mg | MDE Replacement | ||
Q2 2022 | TITANIUM DIOXIDE | ORAL | CAPSULE | 74.20 mg | MDE Replacement | ||
Q3 2022 | TITANIUM DIOXIDE | ORAL | CAPSULE | 4mg | MDE Replacement | ||
Q2 2022 | TRIETHYL CITRATE | ORAL | CAPSULE, COATED, EXTENDED RELEASE | 7.09 mg | MDE Replacement | ||
Q3 2022 | TRIETHYL CITRATE | ORAL | CAPSULE, COATED, EXTENDED RELEASE | 7mg | MDE Replacement | ||
Q2 2022 | TRIMETHYLSILYL TREATED DIMETHICONOL/TRIMETHYLSILOXYSILICATE CROSSPOLYMER (35/65 W/W; 50000000 PA.S) | TRANSDERMAL | SYSTEM | 44.51 mg | MDE Replacement | ||
Q3 2022 | TRIMETHYLSILYL TREATED DIMETHICONOL/TRIMETHYLSILOXYSILICATE CROSSPOLYMER (35/65 W/W; 50000000 PA.S) | TRANSDERMAL | SYSTEM | 45mg | MDE Replacement | ||
Q2 2022 | TRIMETHYLSILYL TREATED DIMETHICONOL/TRIMETHYLSILOXYSILICATE CROSSPOLYMER (45/55 W/W; 100000 PA.S) | TRANSDERMAL | FILM, EXTENDED RELEASE | 228.23 mg | MDE Replacement | ||
Q3 2022 | TRIMETHYLSILYL TREATED DIMETHICONOL/TRIMETHYLSILOXYSILICATE CROSSPOLYMER (45/55 W/W; 100000 PA.S) | TRANSDERMAL | FILM, EXTENDED RELEASE | 704mg | MDE Replacement | ||
Q2 2022 | TRISODIUM CITRATE DIHYDRATE | TOPICAL | CLOTH | 1.68 mg | MDE Replacement | ||
Q3 2022 | TRISODIUM CITRATE DIHYDRATE | TOPICAL | CLOTH | 2mg | MDE Replacement | ||
Q2 2022 | TROLAMINE | TOPICAL | CREAM, AUGMENTED | 1.00 %w/w | MDE Replacement | ||
Q3 2022 | TROLAMINE | TOPICAL | CREAM, AUGMENTED | 20mg | MDE Replacement | ||
Q2 2022 | TROMETHAMINE | INTRAVENOUS | INJECTION, SOLUTION | 1.21 %w/v | MDE Replacement | ||
Q3 2022 | TROMETHAMINE | INTRAVENOUS | INJECTION, SOLUTION | 300mg | MDE Replacement | ||
Q2 2022 | VEGETABLE OIL GLYCERIDE, HYDROGENATED | ORAL | TABLET, EXTENDED RELEASE | 35 mg | MDE Replacement | ||
Q3 2022 | VEGETABLE OIL GLYCERIDE, HYDROGENATED | ORAL | TABLET, EXTENDED RELEASE | 77mg | MDE Replacement | ||
Q2 2022 | VEGETABLE OIL, HYDROGENATED | ORAL | CAPSULE | 261.00 mg | MDE Replacement | ||
Q3 2022 | VEGETABLE OIL, HYDROGENATED | ORAL | CAPSULE | 311mg | MDE Replacement | ||
Q2 2022 | WHITE WAX | ORAL | CAPSULE, EXTENDED RELEASE | 15.30 mg | MDE Replacement | ||
Q3 2022 | WHITE WAX | ORAL | CAPSULE, EXTENDED RELEASE | 71mg | MDE Replacement | ||
Q2 2022 | XANTHAN GUM | ORAL | PASTE | 35.00 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | XANTHAN GUM | ORAL | PASTE | 1050mg | MDE Replacement | ||
Q2 2022 | XYLITOL | ORAL | PASTE | 6.00 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | XYLITOL | ORAL | PASTE | 180mg | MDE Replacement | ||
Q2 2022 | YELLOW WAX | ORAL | CAPSULE | 16.80 mg | MDE Replacement | ||
Q3 2022 | YELLOW WAX | ORAL | CAPSULE | 40mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: July 1, 2022
Database Last Updated: July 18, 2022